B

BLSM

BLSM

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
100%Bullish
Buy/Sell Ratio100% buys
BearishBullish
BLSM Live QuoteReal-time
$14.41
$1.19(-7.63%)1M
Day Range$13.62 – $15.07
Open$14.36
Previous Close$14.59
Volume215.2K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$463.74M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-10.38
Price to Book2.3
Dividend Yield0.65%
Beta (Volatility)1.18
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $14.41 (20%)
Low: $11.02High: $27.99
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$35.40-76.4% upside

Insider Buys

1

$25.17M

Insider Sales

0

$0

Total Volume

$25.17M

1 transactions

Net Activity

+$25.17M

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
80CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Strong buying bias: purchases represent 100% of total transaction value.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
M
1

Multiple Insiders

5 Insiders

1 buys0 sells

$25.17M total

Trading History
BLSM insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Aug 7, 2026

3 months ago

Multiple Insiders

5 Insiders

Insider
Buy1.57M$16.00$25.17M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
BLSM Buy Conviction100%
Industry Rank#0 of 569
Volume Contribution0.2%
Total Industry Activity$16.52B

BLSM has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for BLSM

Over the last 90 days, corporate insiders at BLSM (BLSM) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $25.17M.

The net insider activity for BLSM shows a net buying bias of $25.17M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Purchase by Multiple Insiders (5 Insiders), who traded 1.57M shares valued at $25.17M on Aug 7, 2026.

Live Market News & Developments
Aggregated real-time headlines for BLSM (BLSM)
6 updates

Spouses report the same shareholding in BlossomHill Therapeutics (BLSM).

Stock Titan3d ago

BLSM - BlossomHill Therapeutics Inc Stock Price and Quote

Finviz104d ago

What is the current Price Target and Forecast for BlossomHill Therapeutics, Inc. (BLSM)

Zacks Investment Research102d ago

BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price (BLSM)

Seeking Alpha23d ago

Insider Purchase: Chief Financial Officer of $BLSM Buys 700 Shares

Quiver Quantitative102d ago

BlossomHill Therapeutics (Nasdaq:BLSM) - Stock Analysis

Simply Wall St103d ago

FAQs About BLSM Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for BLSM.

Based on SEC Form 4 disclosures, the Insider Confidence Score for BLSM is currently 80/100, which reflects a strong accumulation bias. This calculation accounts for a total of 1 purchases and 0 sales by company executives over the last 90 days.

The CEO Conviction Index for BLSM is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.